Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies…
What Is OMass Therapeutics
OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.
The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, focusing on membrane receptors.
Latest News
Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high…
– OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton – Oxford, 25 February 2020 – OMass Therapeutics…
– Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders – Oxford, 17 February 2020 –…